Astrazeneca (AZN) Receivables - Other (2016 - 2025)
Astrazeneca (AZN) has 3 years of Receivables - Other data on record, last reported at $2.0 billion in Q4 2025.
- For Q4 2025, Receivables - Other rose 27.74% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $2.0 billion, up 27.74%, while the annual FY2025 figure was $2.0 billion, 27.74% up from the prior year.
- Receivables - Other reached $2.0 billion in Q4 2025 per AZN's latest filing, up from $1.6 billion in the prior quarter.
- Across five years, Receivables - Other topped out at $2.0 billion in Q4 2025 and bottomed at $1.6 billion in Q4 2024.
- Average Receivables - Other over 3 years is $1.7 billion, with a median of $1.6 billion recorded in 2023.
- Peak YoY movement for Receivables - Other: fell 3.66% in 2024, then grew 27.74% in 2025.
- A 3-year view of Receivables - Other shows it stood at $1.6 billion in 2023, then dropped by 3.66% to $1.6 billion in 2024, then grew by 27.74% to $2.0 billion in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $2.0 billion in Q4 2025, $1.6 billion in Q4 2024, and $1.6 billion in Q4 2023.